Literature DB >> 10563792

The thumb domain of the P51-subunit is essential for activation of HIV reverse transcriptase.

M C Morris1, C Berducou, J Mery, F Heitz, G Divita.   

Abstract

The biologically relevant and active form of human immunodeficiency virus reverse transcriptase is a heterodimer produced in a two-step dimerization process. Dimerization involves first the rapid association of the two subunits, followed by a slow conformational change yielding a fully active form. In the present study, we demonstrate that the interaction between the thumb domain of p51 and the RNase-H domain of p66 plays a major role in an essential conformational change required for proper folding of the primer/template and the tRNA-binding site, for maturation and for activation of heterodimeric reverse transcriptase. A synthetic peptide derived from the sequence within the thumb domain of p51, which forms the interface with the RNase-H domains of p66, binds heterodimeric reverse transcriptase with an apparent dissociation constant in the nanomolar range and selectively inhibits activation of heterodimeric reverse transcriptase with an inhibition constant of 1.2 microM. A detailed study of the mechanism of inhibition reveals that this peptide does not require dissociation of heterodimeric RT for efficient inhibition and does not affect subunit association, but interferes with the conformational change required for activation of heterodimeric reverse transcriptase, resulting in a decrease in the affinity of reverse transcriptase for the tRNA and an increase in the stability of the primer/template/reverse transcriptase complex. We have previously proposed that the dimeric nature of reverse transcriptase represents an interesting target for the design of antiviral agents. On the basis of this work, we propose that the conformational changes involved in the activation of reverse transcriptase similarly represent an important target for the design of novel antiviral compounds.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10563792     DOI: 10.1021/bi9914558

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.

Authors:  Anita Y M Howe; Huiming Cheng; Ian Thompson; Srinivas K Chunduru; Steve Herrmann; John O'Connell; Atul Agarwal; Rajiv Chopra; Alfred M Del Vecchio
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Domain structure and three-dimensional model of a group II intron-encoded reverse transcriptase.

Authors:  Forrest J H Blocker; Georg Mohr; Lori H Conlan; Li Qi; Marlene Belfort; Alan M Lambowitz
Journal:  RNA       Date:  2004-12-01       Impact factor: 4.942

3.  Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.

Authors:  Michael E Abram; Michael A Parniak
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  Peptides Mimicking the β7/β8 Loop of HIV-1 Reverse Transcriptase p51 as "Hotspot-Targeted" Dimerization Inhibitors.

Authors:  Pedro A Sánchez-Murcia; Sonia de Castro; Carlos García-Aparicio; M Angeles Jiménez; Angela Corona; Enzo Tramontano; Nicolas Sluis-Cremer; Luis Menéndez-Arias; Sonsoles Velázquez; Federico Gago; María-José Camarasa
Journal:  ACS Med Chem Lett       Date:  2020-01-24       Impact factor: 4.345

5.  Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.

Authors:  Gilberto Betancor; Maria C Puertas; María Nevot; César Garriga; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

6.  Functional multimerization of the human telomerase reverse transcriptase.

Authors:  T L Beattie; W Zhou; M O Robinson; L Harrington
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

7.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20

Review 8.  Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review.

Authors:  Olga Tarasova; Vladimir Poroikov; Alexander Veselovsky
Journal:  Molecules       Date:  2018-05-21       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.